

Peter C Grayson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6352820/publications.pdf>

Version: 2024-02-01

100
papers

5,259
citations

109137

35
h-index

98622

67
g-index

101
all docs

101
docs citations

101
times ranked

3952
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal Characterization of Vascular Inflammation and Disease Activity in Takayasu Arteritis and Giant Cell Arteritis: A Single-Center Prospective Study. <i>Arthritis Care and Research</i> , 2023, 75, 1362-1370.	1.5	3
2	Association of ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography Activity With Angiographic Progression of Disease in Large Vessel Vasculitis. <i>Arthritis and Rheumatology</i> , 2023, 75, 98-107.	2.9	14
3	Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2022, 74, 1013-1018.	1.5	4
4	Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis. <i>Arthritis Care and Research</i> , 2022, 74, 1269-1276.	1.5	5
5	Comparing Semiquantitative and Qualitative Methods of Vascular ¹⁸ F-FDG PET Activity Measurement in Large-Vessel Vasculitis. <i>Journal of Nuclear Medicine</i> , 2022, 63, 280-286.	2.8	18
6	Discordance in patient and physician global assessment in relapsing polychondritis. <i>Rheumatology</i> , 2022, 61, 2025-2033.	0.9	1
7	VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 665-670.	2.9	46
8	Artificial Intelligence in Vascular-PET. <i>PET Clinics</i> , 2022, 17, 95-113.	1.5	6
9	A prospective observational cohort study and systematic review of 40 patients with mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151924.	1.6	4
10	Case 2-2022: A 70-Year-Old Man with a Recurrent Left Pleural Effusion. <i>New England Journal of Medicine</i> , 2022, 386, 274-283.	13.9	1
11	Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu's arteritis. <i>Rheumatology</i> , 2022, 61, 4047-4055.	0.9	10
12	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 386-392.	2.9	50
13	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 309-314.	0.5	157
14	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	2.9	71
15	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 321-326.	0.5	112
16	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 400-406.	2.9	62
17	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 315-320.	0.5	145
18	Orbital and periorbital inflammation in VEXAS syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 338-341.	0.6	18

#	ARTICLE	IF	CITATIONS
19	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. <i>Arthritis Care and Research</i> , 2022, 74, 538-548.	1.5	13
20	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. <i>Arthritis and Rheumatology</i> , 2022, 74, 586-596.	2.9	13
21	Response to: Correspondence on a€ 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitisâ€™™ by Joanna C Robson <i>et al</i> and a€ 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitisâ€™™ by Ravi Suppiah <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrheumdis-2022-222362.	0.5	12
22	Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond. <i>Rheumatology</i> , 2022, 61, 3149-3160.	0.9	16
23	Diseases of blood vessels: Immune system involvement in vasculitis and vasculopathy. <i>Seminars in Immunopathology</i> , 2022, 44, 255-258.	2.8	2
24	VEXAS Syndrome and Disease Taxonomy in Rheumatology. <i>Arthritis and Rheumatology</i> , 2022, 74, 1733-1736.	2.9	9
25	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	12
26	Atherosclerotic Plaque Burden on Abdominal CT: Automated Assessment With Deep Learning on Noncontrast and Contrast-enhanced Scans. <i>Academic Radiology</i> , 2021, 28, 1491-1499.	1.3	22
27	Sequenceâ€™Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i>. <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	2.9	34
28	Effects of the COVIDâ€™19 Pandemic on Patients Living With Vasculitis. <i>ACR Open Rheumatology</i> , 2021, 3, 17-24.	0.9	10
29	Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis. <i>Rheumatology</i> , 2021, 60, 4384-4389.	0.9	34
30	Aortitis: recent advances, current concepts and future possibilities. <i>Heart</i> , 2021, 107, 1620-1629.	1.2	18
31	VEXAS Syndrome. <i>Blood</i> , 2021, 137, 3591-3594.	0.6	63
32	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€™ Associated Vasculitis. <i>Arthritis Care and Research</i> , 2021, 73, 1088-1105.	1.5	90
33	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€™ Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1366-1383.	2.9	249
34	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1349-1365.	2.9	231
35	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis and Rheumatology</i> , 2021, 73, 1384-1393.	2.9	32
36	Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis Withâ€™Polyangiitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1703-1712.	2.9	14

#	ARTICLE	IF	CITATIONS
37	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis Care and Research</i> , 2021, 73, 1061-1070.	1.5	15
38	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 1071-1087.	1.5	61
39	Somatic Mutations in <i>UBA1</i> Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. <i>Arthritis and Rheumatology</i> , 2021, 73, 1886-1895.	2.9	125
40	VEXAS syndrome: An inflammatory and hematologic disease. <i>Seminars in Hematology</i> , 2021, 58, 201-203.	1.8	14
41	Reply LTE, On Semi-quantitative Methods for Assessing Vascular 18FDG-PET Activity in Large-Vessel Vasculitis. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.263158.	2.8	1
42	Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study. <i>Blood</i> , 2021, 138, 2608-2608.	0.6	7
43	ACR Appropriateness Criteria® Noncerebral Vasculitis. <i>Journal of the American College of Radiology</i> , 2021, 18, S380-S393.	0.9	6
44	Large-vessel vasculitis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 93.	18.1	74
45	Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 99-107.	1.0	48
46	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	0.9	33
47	Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 71-76.	1.6	38
48	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	1.5	77
49	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 667-676.	2.9	33
50	Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 262-267.	0.5	32
51	Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 433-434.	0.5	19
52	Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient-, Physician-, Imaging-, and Laboratory-Based Assessments. <i>Arthritis Care and Research</i> , 2020, 72, 1296-1304.	1.5	23
53	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 2167-2168.	2.9	0
54	Somatic Mutations in <i>UBA1</i> and Severe Adult-Onset Autoinflammatory Disease. <i>New England Journal of Medicine</i> , 2020, 383, 2628-2638.	13.9	580

#	ARTICLE	IF	CITATIONS
55	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. <i>Trials</i> , 2020, 21, 362.	0.7	14
56	Comment on: Derivation of an angiographically based classification system in Takayasu's arteritis: reply. <i>Rheumatology</i> , 2020, 59, 1184-1185.	0.9	1
57	Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 1396-1402.	2.9	24
58	Utility of the Brief Illness Perception Questionnaire to Monitor Patient Beliefs in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1785-1792.	1.0	11
59	Myelodysplasia and Bone Marrow Manifestations of Somatic <i>UBA1</i> Mutated Autoinflammatory Disease. <i>Blood</i> , 2020, 136, 20-21.	0.6	17
60	Clinical Factors Associated with Time-Specific Distribution of ¹⁸ F-Fluorodeoxyglucose in Large-Vessel Vasculitis. <i>Scientific Reports</i> , 2019, 9, 15180.	1.6	21
61	Sarcoidosis Concomitant With Takayasu Arteritis, Identified by Advanced Molecular Imaging. <i>Arthritis and Rheumatology</i> , 2019, 71, 990-990.	2.9	5
62	Stenosis and Pseudostenosis of the Upper Extremity Arteries in Large-Vessel Vasculitis. <i>ACR Open Rheumatology</i> , 2019, 1, 156-163.	0.9	6
63	MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease. <i>Cell Systems</i> , 2019, 8, 380-394.e4.	2.9	92
64	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	0.9	37
65	109. ¹⁸ F-IMAGING ACQUISITION TECHNIQUE INFLUENCES INTERPRETATION OF POSITRON EMISSION TOMOGRAPHY VASCULAR ACTIVITY IN LARGE-VESEL VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	1
66	Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. <i>Blood</i> , 2019, 134, 395-406.	0.6	115
67	The Role of Vascular Imaging to Advance Clinical Care and Research in Large-Vessel Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 20-35.	0.6	14
68	Patient-perceived Burden of Disease in Pediatric Relapsing Polychondritis. <i>Journal of Rheumatology</i> , 2019, 46, 1627-1633.	1.0	2
69	Vascular calcification in patients with large-vessel vasculitis compared to patients with hyperlipidemia. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1068-1073.	1.6	19
70	Comparison of magnetic resonance angiography and ¹⁸ F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1165-1171.	0.5	101
71	Use of "Provisional" Designation for Response Criteria. <i>Arthritis Care and Research</i> , 2018, 70, 811-812.	1.5	3
72	Patient Perception of Disease-Related Symptoms and Complications in Relapsing Polychondritis. <i>Arthritis Care and Research</i> , 2018, 70, 1124-1131.	1.5	16

#	ARTICLE	IF	CITATIONS
73	¹⁸ Fluorodeoxyglucose Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 439-449.	2.9	241
74	Brief Report: Drugs Implicated in Systemic Autoimmunity Modulate Neutrophil Extracellular Trap Formation. <i>Arthritis and Rheumatology</i> , 2018, 70, 468-474.	2.9	34
75	Drug-induced lupus: Traditional and new concepts. <i>Autoimmunity Reviews</i> , 2018, 17, 912-918.	2.5	74
76	Characterisation of the nasal microbiota in granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1448-1453.	0.5	37
77	Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus. <i>JCI Insight</i> , 2018, 3, .	2.3	126
78	Vasculitis Around the World: Epidemiologic Insights into Causality and a Need for Global Partnerships. <i>Journal of Rheumatology</i> , 2017, 44, 136-139.	1.0	8
79	Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?. <i>Rheumatology</i> , 2017, 56, 1154-1161.	0.9	89
80	A role for muscarinic receptors in neutrophil extracellular trap formation and levamisole-induced autoimmunity. <i>JCI Insight</i> , 2017, 2, e89780.	2.3	69
81	Review: Neutrophils as Invigorated Targets in Rheumatic Diseases. <i>Arthritis and Rheumatology</i> , 2016, 68, 2071-2082.	2.9	24
82	Abnormal molecular response to Takayasu arteritis causing extensive large-vessel calcification. <i>Journal of Vascular Surgery Cases and Innovative Techniques</i> , 2016, 2, 190-192.	0.3	1
83	A small n sequential multiple assignment randomized trial design for use in rare disease research. <i>Contemporary Clinical Trials</i> , 2016, 46, 48-51.	0.8	31
84	At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. <i>Journal of Leukocyte Biology</i> , 2016, 99, 253-264.	1.5	172
85	Clinical Images: Diagnosis of Giant Cell Arteritis in an Asymptomatic Patient. <i>Arthritis and Rheumatology</i> , 2015, 68, n/a-n/a.	2.9	7
86	What matters for patients with vasculitis?. <i>Presse Medicale</i> , 2015, 44, e267-e272.	0.8	5
87	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1922-1932.	2.9	116
88	Brief Report: Defining the Nasal Transcriptome in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , 2015, 67, 2233-2239.	2.9	17
89	Lumpers and Splitters: Ongoing Issues in the Classification of Large Vessel Vasculitis. <i>Journal of Rheumatology</i> , 2015, 42, 149-151.	1.0	6
90	The informational needs of patients with ANCA-associated vasculitis--development of an informational needs questionnaire. <i>Rheumatology</i> , 2014, 53, 1414-1421.	0.9	20

#	ARTICLE	IF	CITATIONS
91	Causal Attributions about Disease Onset and Relapse in Patients with Systemic Vasculitis. Journal of Rheumatology, 2014, 41, 923-930.	1.0	15
92	P10. Review of the expert panel methodology in the diagnostic and classification criteria for vasculitis study: a pilot study. Rheumatology, 2014, 53, i15-i16.	0.9	1
93	ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clinical and Experimental Nephrology, 2013, 17, 619-621.	0.7	158
94	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. Journal of Rheumatology, 2013, 40, 1905-1912.	1.0	40
95	Illness Perceptions and Fatigue in Systemic Vasculitis. Arthritis Care and Research, 2013, 65, 1835-1843.	1.5	51
96	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Annals of the Rheumatic Diseases, 2012, 71, 1329-1334.	0.5	218
97	Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. Rheumatology, 2012, 51, 100-109.	0.9	285
98	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. Journal of Rheumatology, 2012, 39, 303-309.	1.0	51
99	Nomenclature and classification of vasculitis — update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS). Clinical and Experimental Immunology, 2011, 164, 11-13.	1.1	76
100	317. Re-Appraisal of the 1990 American College of Rheumatology Classification Criteria for Systemic Vasculitis: Analysis of Data from the Diagnostic and Classification Criteria in Vasculitis Study. Rheumatology, 0, , .	0.9	0